HENDERSON, NV / ACCESSWIRE / January 3, 2019 / Cannabis had a huge 2018. Canada became the first industrialized country in the world to legalize recreational pot in October, with a handful of U.S. states choosing to give the legalize cannabis in some capacity. The U.S. FDA also approved its very first cannabis-derived drug. 2019 could be an even bigger year for the industry, here are a few companies that could lead the way.
An absolutely fascinating company that we have discovered is, OWC Pharmaceutical Research Corp. (OWCP). OWCP is well positioned in almost $100 billion of market opportunity between their two products, one is a pain-relieving soluble tablet, the other a topical cream set to combat conditions like Psoriasis. If this is your first time hearing about OWCP, start doing your own due diligence immediately. This cannabinoid-based biotech firm is well positioned and could take off once the street discovers it. Do your due diligence today on OWCP
Today we are highlighting: OWC Pharmaceutical Research Corp. (OWCP), Aphria, Inc. (APHA), MedMen Enterprises, Inc. (OTCQX: MMNFF ), Aurora Cannabis, Inc. (NYSE: ACB ), and Tilray, Inc. (NASDAQ: TLRY ).
OWC Pharmaceutical Research Corp. (OWCP) (Market Cap: $17.74M Share Price: $0.12) a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, has successfully produced its cannabinoid-enriched sublingual disintegrating tablet, specifically developed as smoking substitute. OWCP will now be able to begin its clinical testing program for this dosing form. OWCP has received an IRB approval to conduct a pharmaco-kinetic (PK) safety study of its sublingual tablet.
OWCP is also developing a cannabis-based topical ointment and is close to completing its first ever safety study, conducted at Sheba Medical Center, Tel Hashomer, Israel. The company also reported recently that it has been granted a patent in the Czech Republic covering its topical formulations for skin disorders.
WCP’s multiple products makes them desirable to a wider variety of larger companies, at this stage the company is worth a serious look.
Aphria, Inc. (APHA) (Market Cap: $1.51B Share Price: $6.02), announced that its Colombian subsidiary, Colcanna SAS has signed an exclusive agreement with the Federación Medica Colombiana, a national guild that oversees the ethical exercise of the medical profession in Colombia, to jointly develop an academic curriculum on the medicinal use of cannabis.
MedMen Enterprises, Inc. (MMNFF) (Market Cap: $1.45B, Share Price: $3.15) announced that further to the binding letter of intent in respect of a business combination transaction announced on October 11, 2018, the Company and PharmaCann, LLC entered into a definitive business combination agreement pursuant to which MedMen and PharmaCAnn will combine their respective businesses.
Aurora Cannabis, Inc. (ACB) (Market Cap: $4.92B Share Price: $4.95) entered into an agreement to invest $10 million by way of a brokered private placement in High Tide Inc., a privately held, Alberta-based, retaiol-focused cannabis and lifestyle accessories company.
Tilray, Inc. (TLRY) (Market Cap: $6.56B, Share Price: $70.62) recently announced a partnership with beverage giant and the world’s largest beer maker, AB InBev (BUD) to research cannabis infused drinks.
This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal Consulting has agreed to a one month term consulting agreement with OWCP dated 12/25/18. The agreement calls for $20,000 in cash per month. All payments were made directly by OWC Pharmaceutical Research, Corp. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. OWCP was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer.
SOURCE: ACR Communications LLC